Ropes & Gray Advises Blueprint Medicines in $600+ Million Collaboration with Zai Lab in Greater China
Ropes & Gray advised Blueprint Medicines in an exclusive collaboration and licensing agreement with Zai Lab Limited for the development and commercialization for treatment of patients with epidermal growth factor receptor-driven non-small cell lung cancer in mainland China, Hong Kong, Macau and Taiwan. The collaboration was announced on November 9.
Under the terms of the agreement, Blueprint Medicines will receive an upfront cash payment of $25 million and will be eligible to receive up to $590 million in potential future milestone payments and royalties. Zai Lab will be responsible for all development costs in Greater China and will receive rights to develop and exclusively commercialize two EGFR therapies in the region.
The Ropes & Gray team representing Blueprint Medicines included IP transactions partner Hannah England (Freeman).